ROSEN, LEADING TRIAL LAWYERS, Encourages Commvault Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class...

RGC DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important...

LG Display to showcase world's largest Gaming OLED lineup in Taiwan

ROSEN, NATIONAL TRIAL COUNSEL, Encourages FS KKR Capital Corp. Investors to Secure Counsel Before Important Deadline in Securities Class...

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Graphic Packaging Holding Company Investors to Secure Counsel Before Important Deadline in...

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026...

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and...

ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in...

New Taipei City Showcases Smart Manufacturing Strength at AUTOMATE 2026

MICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026

AMD Bundles Carbice Ice Pad with Ryzen™ 7 5800X3D

Carbice and Noctua Partner to Bring Advanced Thermal Pad Technology to DIY PC Builders

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced...

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein)...

BriaCell Therapeutics Announces Pricing of Offering

Self OPEN EMDR: The Honest Pros and Cons of Doing It Without a Therapist

TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First...

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026